Bioventus Inc. (BVS)
After hours:
| Previous close | 4.52 |
| Open | 4.80 |
| Bid | 5.05 x 1400 |
| Ask | 5.64 x 1000 |
| Day's range | 4.69 - 5.52 |
| 52-week range | 0.80 - 5.52 |
| Volume | |
| Avg. volume | 160,844 |
| Market cap | 321.755M |
| Beta (5Y monthly) | 0.38 |
| PE ratio (TTM) | N/A |
| EPS (TTM) | -2.56 |
| Earnings date | 07 Nov 2023 |
| Forward dividend & yield | N/A (N/A) |
| Ex-dividend date | N/A |
| 1y target est | 4.83 |
GlobeNewswireBioventus Agrees to Nationwide Contract with Aetna™ Medicare Advantage Plans for DUROLANE® for Knee Osteoarthritis
DURHAM, N.C., Dec. 06, 2023 (GLOBE NEWSWIRE) -- Bioventus Inc. (Nasdaq: BVS) (“Bioventus” or the “Company”), a global leader in innovations for active healing, has agreed to a nationwide contract with Aetna™ Medicare Advantage plans. Beginning January 1, 2024, over 3 million Aetna™ Medicare Advantage plan members will have access to DUROLANE to treat knee osteoarthritis (OA) pain. DUROLANE, is a single-injection hyaluronic acid (HA)-based joint-fluid treatment for patients. DUROLANE will be one
Insider MonkeyBioventus Inc. (NASDAQ:BVS) Q3 2023 Earnings Call Transcript
Bioventus Inc. (NASDAQ:BVS) Q3 2023 Earnings Call Transcript November 12, 2023 Operator: Thank you for standing by. My name is Dustin, and I will be your conference operator today. This time, I would like to welcome everyone to Bioventus Inc. Third Quarter 2023 Earnings Conference Call. [Operator Instructions] At this time, I’d like to turn […]
- GlobeNewswire
Bioventus Reports Third Quarter Financial Results; Raises Full Year 2023 Financial Guidance
DURHAM, N.C., Nov. 07, 2023 (GLOBE NEWSWIRE) -- Bioventus Inc. (Nasdaq: BVS) ("Bioventus" or "the Company"), a global leader in innovations for active healing, today reported financial results for the three and nine months ended September 30, 2023. Q3 Financial Summary: Net Sales of $120.8 million, down $7.9 million, or 6.1%, year-over-year as reported (6.3% constant currency*). Excluding revenues from divested wound assets, underlying organic sales decreased $0.6 million, or 0.5% year-over-year
